The effectiveness of gentamicin in the treatment of Neisseria gonorrhoeae: A systematic review

Systematic Reviews

Volumn 3, Issue 1, 2014, Pages

  Hathorn, Emma ^a   Dhasmana, Divya ^a   Duley, Lelia ^b   Ross, Jonathan D C ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Gentamicin; Gonorrhoea; Neisseria gonorrhoeae; Treatment

Indexed keywords

GENTAMICIN; ANTIINFECTIVE AGENT;

ABSENCE OF SIDE EFFECTS; ANTIBIOTIC SENSITIVITY; ARTICLE; DISEASE SURVEILLANCE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DYSURIA; GENITAL PAIN; GENITAL SYSTEM DISEASE; GONORRHEA; HUMAN; META ANALYSIS; NEISSERIA GONORRHOEAE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; INTRAMUSCULAR DRUG ADMINISTRATION;

ANTI-BACTERIAL AGENTS; GENTAMICINS; GONORRHEA; HUMANS; INJECTIONS, INTRAMUSCULAR; NEISSERIA GONORRHOEAE; TREATMENT OUTCOME;

EID: 84928045158     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/2046-4053-3-104     Document Type: Article

References (38)

1. Health Protection England Sexually transmitted infections and chlamydia screening in England 2012. Health Prot Rep 2013, 7(23):8-21. Health Protection England.
2. World Health Organization Global incidence and prevalence of selected curable sexually transmitted infections, 2008. [http://www.who.int/reproductivehealth/publications/rtis/stisestimates/en/], World Health Organization.
3. Aghaizu A, Adams EJ, Turner K, Kerry S, Hay P, Simms I, Oakeshott P. What is the cost of pelvic inflammatory disease and how much could be prevented by screening for Chlamydia trachomatis? Cost analysis of the Prevention of Pelvic Infection (POPI) trial. Sex Transm Infect 2011, 87(4):312-317. 10.1136/sti.2010.048694, 21444333.
4. Yeh JM, Hook EW, Goldie SJ. A refined estimate of the average lifetime cost of pelvic inflammatory disease. Sex Transm Dis 2003, 30(5):369-378. 10.1097/00007435-200305000-00001, 12916126.
5. Venkatesh KK, van der Straten A, Cheng H, Cheng H, Montgomery ET, Lurie MN, Chipato T, Ramjee G, Blanchard K, Padian NS, Mayer KH, de Bruyn G. The relative contribution of viral and bacterial sexually transmitted infections on HIV acquisition in southern African women in the methods for improving reproductive health in Africa study. Int J STD AIDS 2011, 22(4):218-224. 10.1258/ijsa.2010.010385, 21515755.
6. Watson-Jones D, Baisley K, Weiss HA, Tanton C, Changalucha J, Everett D, Chirwa T, Ross D, Clayton T, Hayes R. Risk factors for HIV incidence in women participating in an HSV suppressive treatment trial in Tanzania. AIDS 2009, 23(3):415-422. 10.1097/QAD.0b013e32831ef523, 3223401, 19114859.
7. Pathela P, Braunstein S, Blank S, Schillinger J. HIV incidence and time to diagnosis among men with bacterial rectal infections, New York City. Sex Transm Infect 2011, 87(Suppl 1):A184.
8. Cohen MS, Hoffman IF, Royce RA, Kazembe P, Dyer JR, Daly CC, Zimba D, Vernazza PL, Maida M, Fiscus SA, Eron JJ. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1: AIDSCAP Malawi Research Group. Lancet 1997, 349(9069):1868-1873. 10.1016/S0140-6736(97)02190-9, 9217758.
9. Ghys PD, Fransen K, Diallo MO, Ettiègne-Traoré V, Coulibaly IM, Yeboué KM, Kalish ML, Maurice C, Whitaker JP, Greenberg AE, Laga M. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan. Cote d'Ivoire AIDS 1997, 11(12):F85-F93.
10. Levine WC, Pope V, Bhoomkar A, Tambe P, Lewis JS, Zaidi AA, Farshy CE, Mitchell S, Talkington DF. Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases. J Infect Dis 1998, 177(1):167-174. 10.1086/513820, 9419184.
11. HPA Guidance for gonorrhoea testing in England and Wales, 2010. [http://www.bashh.org/BASHH/Guidelines/Guidelines/BASHH/Guidelines/Guidelines.aspx].
12. Bignell C. European (IUSTI/WHO) guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2009, 20(7):453-457. 10.1258/ijsa.2009.009160, 19541885.
13. Smith DW, Tapsall JW, Lum J. Guidelines for the use and interpretation of nucleic acid detection tests for Neisseria gonorrhoea in Australia: a position paper on behalf of the Public Health Laboratory Network. [http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi2904-pdf-cnt.htm/$FILE/cdi2904b.pdf].
14. CDC Sexually Transmitted Diseases Guidelines, 2010: gonococcal infections. [http://www.cdc.gov/std/treatment/2010/gonococcal-infections.htm].
15. World Health Organization Guidelines for the management of sexually transmitted diseases. [http://www.who.int/hiv/pub/sti/en/STIGuidelines2003.pdf], World Health Organization.
16. Bignell C, FitxGerald M. UK national guideline for the management of gonorrhoea in adults, 2011. [http://www.bashh.org/BASHH/Guidelines/Guidelines/BASHH/Guidelines/Guidelines.aspx].
17. Government of South Australia, Communicable Disease Control Branch Revision of treatment guidelines for uncomplicated gonorrhoea. [http://www.health.wa.gov.au/diseasewatch/vol17_issue3/gonorrhoeae-treatment.cfm], Government of South Australia, Communicable Disease Control Branch.
18. European Centre for Disease Prevention and Control Response plan to control and manage the threat of multi-drug resistant gonorrhoea in Europe. [http://www.ecdc.europa.eu/en/publications/Publications/1206-ECDC-MDR-gonorrhoea-response-plan.pdf], European Centre for Disease Prevention and Control.
19. HPA GRASP 2010 Report. [http://webarchive.nationalarchives.gov.uk/20140714084352/http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1316016752917].
20. CDC 2010 STD Surveillance Report: Gonorrhoea. [http://www.cdc.gov/std/stats10/gonorrhea.htm].
21. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, Nakayama S, Kitawaki J, Unemo M. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011, 55(7):3538-3545. 10.1128/AAC.00325-11, 3122416, 21576437.
22. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in Europe (France): novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012, 56(3):1273-1280. 10.1128/AAC.05760-11, 3294892, 22155830.
23. Carnicer-Pont D, Smithson A, Fina-Homar E, Bastida MT. First cases of Neisseria gonorrhoeae resistant to ceftriaxone in Catalonia, Spain, May 2011. Enferm Infecc Microbiol Clin 2012, 30(4):218-219. 10.1016/j.eimc.2011.11.010, 22244992.
24. Ameyama S, Onodera S, Takahata M, Minami S, Maki N, Endo K, Goto H, Suzuki H, Oishi Y. Mosaic-like structure of penicillin-binding protein 2 gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob Agents Chemother 2002, 46(12):3744-3749. 10.1128/AAC.46.12.3744-3749.2002, 132769, 12435671.
25. Ito M, Deguchi T, Mizutani KS, Yasuda M, Yokoi S, Ito S, Takahashi Y, Ishihara S, Kawamura Y, Ezaki T. Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in Central Japan. Antimicrob Agents Chemother 2005, 49(1):137-143. 10.1128/AAC.49.1.137-143.2005, 538884, 15616287.
26. Tanaka M, Nakayama H, Huruya K, Konomi I, Irie S, Kanayama A, Saika T, Kobayashi I. Analysis of mutations within multiple genes associated with resistance in a clinical isolate of Neisseria gonorrhoeae with reduced ceftriaxone susceptibility that shows a multidrug-resistant phenotype. Int J Antimicrob Agents 2006, 27(1):20-26. 10.1016/j.ijantimicag.2005.08.021, 16318912.
27. Brown LB, Krysiak R, Kamanga G, Mapanje C, Kanyamula H, Banda B, Mhango C, Hoffman M, Kamwendo D, Hobbs M, Hosseinipour MC, Martinson F, Cohen MS, Hoffman IF. Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. Sex Transm Dis 2010, 37:169-172. 10.1097/OLQ.0b013e3181bf575c, 19901860.
28. Lule G, Behets FM, Hoffman IF, Dallabetta G, Hamilton HA, Moeng S, Liomba G, Cohen MS. STD/HIV control in Malawi and the search for affordable and effective urethritis therapy: a first field evaluation. Genitourin Med 1994, 70(6):384-388. 1195302, 7705854.
29. Chisholm SA, Quaye N, Cole MJ, Fredlund H, Hoffmann S, Jensen JS, van de Laar MJ, Unemo M, Ison CA. An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe. J Antimicrob Chemother 2011, 66(3):592-595. 10.1093/jac/dkq476, 21172790.
30. Hathorn E, Dhasmana D, Dule L, Ross J, Harding J. The effectiveness of gentamicin in the treatment of Neisseria gonorrhoeae: a systematic review. PROSPERO: International Prospective Register of Systematic Reviews. 2012: CRD42012002490. [http://www.crd.york.ac.uk/NIHR_PROSPERO/].
31. The Cochrane Collaboration Chapter 8: Assessing risk of bias included studies. [http://handbook.cochrane.org/], The Cochrane Collaboration.
32. Dreyer NA, Velentgas P, Westrich K, Dubois R. The GRACE checklist for rating the quality of observational studies of comparative effectiveness: a tale of hope and caution. JMCP 2014, 20(3):301-308.
33. Iskandar IO, Nahuib F, Gabry L EL. A comparative study of gentamicin, co-trimoxazole and trimethoprim-sulphametrol in acute gonococcal urethritis. J Egypt Med Assoc 1978, 61:489-495.
34. Yoon JY, Kim YT, Kim JH. Treatment of uncomplicated male gonococcal urethritis: kanamycin vs. gentamicin. Korean J Dermatol 1988, 26(2):184-188.
35. Pareek SS, Chowdhury MNH. Comparative study between gentamicin and spectinomycin in the treatment of infections to penicillin-resistant gonococci. Curr Ther Res 1981, 30(2):177-180.
36. Hira SK, Attili VR, Kamanga J, Mkandawire O, Patel JS, Patel MI. Efficacy of gentamicin and kanamycin in the treatment of uncomplicated gonococcl urethritis in Zambia. Sex Transm Dis 1985, 12(1):52-54. 10.1097/00007435-198501000-00011, 3890228.
37. Dowell D, Kirkcaldy RD. Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis. Sex Transm Inf 2012, 88:589-594.
38. Kirkcaldy RD. Treatment of gonorrhoea in an era of emerging cephalosporin resistance and results of a randomised trial of new potential treatment options. Sex Transm Infect 2013, 89:A14-A15. doi:10.1136/sextrans-2013-051184.0043.